Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Bristol-Myers Squibb
The Netherlands Cancer Institute
Sarcoma Oncology Research Center, LLC
Daiichi Sankyo
Ikena Oncology
University Hospital, Ghent
Gritstone bio, Inc.
Tempest Therapeutics
Fate Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
Nektar Therapeutics
Nektar Therapeutics
Infinity Pharmaceuticals, Inc.
Incyte Corporation
Genocea Biosciences, Inc.